1. Home
  2. LOVE vs ACIU Comparison

LOVE vs ACIU Comparison

Compare LOVE & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Lovesac Company

LOVE

The Lovesac Company

HOLD

Current Price

$14.04

Market Cap

193.2M

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.56

Market Cap

213.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOVE
ACIU
Founded
1998
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
193.2M
213.3M
IPO Year
2018
2015

Fundamental Metrics

Financial Performance
Metric
LOVE
ACIU
Price
$14.04
$2.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$27.60
$10.00
AVG Volume (30 Days)
328.4K
254.2K
Earning Date
03-26-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$680,628,000.00
N/A
Revenue This Year
$7.65
$635.38
Revenue Next Year
$8.77
$232.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.33
$1.43
52 Week High
$21.90
$4.00

Technical Indicators

Market Signals
Indicator
LOVE
ACIU
Relative Strength Index (RSI) 65.93 36.68
Support Level $14.04 $2.57
Resistance Level $15.26 $3.92
Average True Range (ATR) 0.74 0.24
MACD 0.43 -0.03
Stochastic Oscillator 90.75 1.15

Price Performance

Historical Comparison
LOVE
ACIU

About LOVE The Lovesac Company

The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.

About ACIU AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: